Craig-Hallum analyst Kevin Ellich maintained a Hold rating on Amedisys and cut his price target to $124 from $132 following the company’s Q4 results. In a research note to investors, Ellich says that while CCH’s EBITDA contribution is expected to ramp from $12M-$14M in 2019 to ~$50M in 2021, and Amedisys has ample dry powder for acquisitions and share repurchases, he believes its premium valuation and the overhang attributable to PDGM will continue to weigh on the stock in the near-term.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.